AllianceBernstein’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $458K | Buy |
8,302
+4,059
| +96% | +$215K | ﹤0.01% | 2776 |
|
|
2026
Q1 | $208K | Buy |
+4,243
| New | +$230K | ﹤0.01% | 3037 |
|
|
2024
Q1 | – | Sell |
-7,580
| Closed | -$281K | – | 3157 |
|
|
2023
Q4 | $281K | Buy |
+7,580
| New | +$272K | ﹤0.01% | 2871 |
|
|
2022
Q3 | – | Sell |
-699,953
| Closed | -$38.1M | – | 3285 |
|
|
2022
Q2 | $38.1M | Buy |
699,953
+569,420
| +436% | +$31.4M | 0.02% | 652 |
|
|
2022
Q1 | $7.11M | Sell |
130,533
-127,625
| -49% | -$6.93M | ﹤0.01% | 1417 |
|
|
2021
Q4 | $14.2M | Buy |
258,158
+197,697
| +327% | +$10.3M | 0.01% | 1079 |
|
|
2021
Q3 | $2.89M | Buy |
+60,461
| New | +$3.04M | ﹤0.01% | 1939 |
|
|
2020
Q1 | – | Sell |
-4,117
| Closed | -$242K | – | 3153 |
|
|
2019
Q4 | $242K | Sell |
4,117
-157,052
| -97% | -$8.74M | ﹤0.01% | 2852 |
|
|
2019
Q3 | $8.6M | Buy |
161,169
+151,223
| +1,520% | +$7.78M | 0.01% | 1111 |
|
|
2019
Q2 | $498K | Buy |
9,946
+3,496
| +54% | +$175K | ﹤0.01% | 2602 |
|
|
2019
Q1 | $337K | Buy |
+6,450
| New | +$322K | ﹤0.01% | 2701 |
|
|
2018
Q2 | – | Sell |
-120,202
| Closed | -$5.87M | – | 3118 |
|
|
2018
Q1 | $5.87M | Buy |
+120,202
| New | +$5.6M | ﹤0.01% | 1130 |
|
|
2016
Q4 | – | Sell |
-10,491
| Closed | -$566K | – | 3023 |
|
|
2016
Q3 | $566K | Sell |
10,491
-4,512
| -30% | -$247K | ﹤0.01% | 2488 |
|
|
2016
Q2 | $813K | Sell |
15,003
-4,006
| -21% | -$211K | ﹤0.01% | 2316 |
|
|
2016
Q1 | $964K | Sell |
19,009
-3,456
| -15% | -$172K | ﹤0.01% | 2121 |
|
|
2015
Q4 | $1.13M | Sell |
22,465
-14,461
| -39% | -$737K | ﹤0.01% | 2052 |
|
|
2015
Q3 | $1.77M | Buy |
36,926
+1,000
| +3% | +$52.1K | ﹤0.01% | 1743 |
|
|
2015
Q2 | $1.87M | Sell |
35,926
-308,329
| -90% | -$17.4M | ﹤0.01% | 1856 |
|
|
2015
Q1 | $19.9M | Sell |
344,255
-1,991
| -0.6% | -$114K | 0.02% | 727 |
|
|
2014
Q4 | $18.5M | Sell |
346,246
-27,012
| -7% | -$1.51M | 0.02% | 724 |
|
|
2014
Q3 | $21.4M | Sell |
373,258
-1,248,326
| -77% | -$76.5M | 0.02% | 674 |
|
|
2014
Q2 | $108M | Buy |
1,621,584
+2,433
| +0.2% | +$165K | 0.09% | 245 |
|
|
2014
Q1 | $108M | Buy |
1,619,151
+141,785
| +10% | +$9.59M | 0.09% | 250 |
|
|
2013
Q4 | $98.6M | Buy |
1,477,366
+1,188,296
| +411% | +$77M | 0.09% | 256 |
|
|
2013
Q3 | $18.1M | Buy |
289,070
+7,573
| +3% | +$487K | 0.02% | 675 |
|
|
2013
Q2 | $17.6M | Buy |
+281,497
| New | +$17.9M | 0.02% | 680 |
|
Other funds holding GSK
JEST
AllianceBernstein's GSK Position: Q2 2026 in Review
AllianceBernstein increased its GSK (GSK) stake by 96% in Q2 2026, buying an estimated $215K and bringing the position to 8,302 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #2776.
AllianceBernstein first reported a position in GSK in Q2 2013 and has held it in 26 quarters since. The position peaked at $108M in Q2 2014. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- AllianceBernstein held 8,302 shares of GSK worth $458K as of Q2 2026.
- AllianceBernstein bought 4,059 GSK shares in Q2 2026, an estimated $215K.
- GSK made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2776 holding.
- AllianceBernstein first reported a position in GSK in Q2 2013 and has held it in 26 quarters since.
- AllianceBernstein's GSK position peaked at $108M in Q2 2014.
- 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.